Cargando…
Read-through approach for stop mutations in Duchenne muscular dystrophy. An update
Dystrophinopathies are allelic conditions caused by deletions, duplications and point-mutations in the DMD gene, located on the X chromosome (Xp21.2). Mutations that prematurely interrupt the dystrophin protein synthesis lead to the most severe clinical form, Duchenne muscular Dystrophy, characteriz...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pacini Editore Srl
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033424/ https://www.ncbi.nlm.nih.gov/pubmed/33870095 http://dx.doi.org/10.36185/2532-1900-041 |
_version_ | 1783676411183104000 |
---|---|
author | Politano, Luisa |
author_facet | Politano, Luisa |
author_sort | Politano, Luisa |
collection | PubMed |
description | Dystrophinopathies are allelic conditions caused by deletions, duplications and point-mutations in the DMD gene, located on the X chromosome (Xp21.2). Mutations that prematurely interrupt the dystrophin protein synthesis lead to the most severe clinical form, Duchenne muscular Dystrophy, characterized by early involvement of muscle strength. There is no known cure for dystrophinopathies. In DMD, treatment with corticosteroids have changed the natural history and the progression of the disease, prolonging ambulation, and slowing the onset of respiratory and cardiac involvement and scoliosis by several years. In the last few years, new perspectives and options are deriving from the discovery of pharmacological approaches able to restore normal, full-length dystrophin and potentially reverse the course of the disease. Read-through (RT) of nonsense mutations, thanks to its ability to bypass the premature stop codon and to act on virtually any region of the dystrophin gene, independently of the location in which the mutation resides, is one of these promising approaches. This non-systematic review shows the different steps that, passing from yeast to humans, have made it possible to use this innovative successful approach to treat serious diseases such as Duchenne muscular dystrophy. |
format | Online Article Text |
id | pubmed-8033424 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Pacini Editore Srl |
record_format | MEDLINE/PubMed |
spelling | pubmed-80334242021-04-15 Read-through approach for stop mutations in Duchenne muscular dystrophy. An update Politano, Luisa Acta Myol Original Article Dystrophinopathies are allelic conditions caused by deletions, duplications and point-mutations in the DMD gene, located on the X chromosome (Xp21.2). Mutations that prematurely interrupt the dystrophin protein synthesis lead to the most severe clinical form, Duchenne muscular Dystrophy, characterized by early involvement of muscle strength. There is no known cure for dystrophinopathies. In DMD, treatment with corticosteroids have changed the natural history and the progression of the disease, prolonging ambulation, and slowing the onset of respiratory and cardiac involvement and scoliosis by several years. In the last few years, new perspectives and options are deriving from the discovery of pharmacological approaches able to restore normal, full-length dystrophin and potentially reverse the course of the disease. Read-through (RT) of nonsense mutations, thanks to its ability to bypass the premature stop codon and to act on virtually any region of the dystrophin gene, independently of the location in which the mutation resides, is one of these promising approaches. This non-systematic review shows the different steps that, passing from yeast to humans, have made it possible to use this innovative successful approach to treat serious diseases such as Duchenne muscular dystrophy. Pacini Editore Srl 2021-03-31 /pmc/articles/PMC8033424/ /pubmed/33870095 http://dx.doi.org/10.36185/2532-1900-041 Text en ©2021 Gaetano Conte Academy - Mediterranean Society of Myology, Naples, Italy https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International) license. The article can be used by giving appropriate credit and mentioning the license, but only for non-commercial purposes and only in the original version. For further information: https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en |
spellingShingle | Original Article Politano, Luisa Read-through approach for stop mutations in Duchenne muscular dystrophy. An update |
title | Read-through approach for stop mutations in Duchenne muscular dystrophy. An update |
title_full | Read-through approach for stop mutations in Duchenne muscular dystrophy. An update |
title_fullStr | Read-through approach for stop mutations in Duchenne muscular dystrophy. An update |
title_full_unstemmed | Read-through approach for stop mutations in Duchenne muscular dystrophy. An update |
title_short | Read-through approach for stop mutations in Duchenne muscular dystrophy. An update |
title_sort | read-through approach for stop mutations in duchenne muscular dystrophy. an update |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033424/ https://www.ncbi.nlm.nih.gov/pubmed/33870095 http://dx.doi.org/10.36185/2532-1900-041 |
work_keys_str_mv | AT politanoluisa readthroughapproachforstopmutationsinduchennemusculardystrophyanupdate |